on Mbiomics GmbH
Mbiomics Secures €30 Million to Advance Microbiome Therapies
mbiomics GmbH, based in Munich, has announced the successful third closing of its Series A round, now totaling €30 million. This funding will support the advancement of microbiome-based therapeutics, focusing on severe and chronic diseases. Existing investors like MIG Fonds and Bayern Kapital participated in the round.
The investment aims to enhance IND-enabling pharmacological data and accelerate GMP manufacturing, as mbiomics prepares for clinical evaluation of MBX-116. This candidate acts as a co-therapy in advanced melanoma, marking the company's shift from platform development to clinical application.
Dr. Johannes B. Woehrstein, CEO, emphasized mbiomics' focus on solving the challenges of scalable microbiome therapeutics. By utilizing AI-driven design and proprietary technology, mbiomics develops live bacterial strains for gut health.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mbiomics GmbH news